CytoReason vs Remepy
CytoReason vs Remepy, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Remepy on 57/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 57/100
- domain rating: 40/100 against 21/100
- headcount: 116 against 75
- funding raised: $128M against $15.0M
- LinkedIn following: 12,830 against 6,458
Remepy
- agent readiness: 40/100 against 21/100
- headcount growth: +105.6% against +13.7%
At a glance
| Measure | CytoReason | Remepy |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Digital therapeutics platform enhancing drug efficacy and safety through personalized software. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Drug Development, Biotech, Life Sciences |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2021 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | CytoReason | Remepy |
|---|---|---|
| Employees | 116 | 75 |
| Headcount growthLast 12 months | +13.7% | +105.6% |
| Total funding | $128M | $15.0M |
| Latest round | Series B | Seed |
| LinkedIn followers | 12,830 | 6,458 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Remepy |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 57/100 |
| Traction | 60/100 | 55/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 30/100 | 38/100 |
| Quality | 78/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 40/100 | 21/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Remepy |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | Webflow |
| Analytics | Segment | Google Analytics 4, Google Tag Manager |
CytoReason vs Remepy: common questions
Which is better, CytoReason or Remepy?
On our 0-100 score CytoReason rates higher (68/100 against 57/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do CytoReason and Remepy compare on the numbers?
CytoReason leads on our overall score (68/100 against 57/100), domain rating (40/100 against 21/100), headcount (116 against 75), funding raised ($128M against $15.0M), LinkedIn following (12,830 against 6,458). Remepy leads on agent readiness (40/100 against 21/100), headcount growth (+105.6% against +13.7%).
Read the full CytoReason review and pricing or the Remepy review and pricing. You can also browse other CytoReason alternatives we track.